Form 4: Vir Biotechnology Director Sells Shares Under 10b5-1 Trading Plan

Vicki L Sato, a director at Vir Biotechnology, sold 10,960 shares of common stock at $12.52 per share on January 8, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Vicki L Sato, a director of Vir Biotechnology, sold 10,960 shares of the company's common stock on January 8, 2025.
• The sale was executed at a price of $12.52 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 29, 2024.
• Following the transaction, Ms. Sato directly owns 1,312,391 shares of Vir Biotechnology common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to a pre-planned stock sale by a director. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives and directors to use 10b5-1 trading plans to avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The use of a 10b5-1 trading plan is a common practice among corporate insiders to manage their stock sales in a compliant manner.
• The sale of 10,960 shares is not unusual for a director of a company of this size.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on shareholder sentiment, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

Form 4, insider trading, Rule 10b5-1, stock sale, Vir Biotechnology, Vicki L Sato, director